Fabian Schmidt

TL;DR: The authors used a yeast-display system to map all mutations to the viral spike receptor-binding domain (RBD) that escape binding by representatives of three potently neutralizing classes of anti-RBD antibodies with high-resolution structures.

TL;DR: This work characterizes the binding affinity and kinetics of different multimeric forms of recombinant ACE2 and Spike-RBD domain, and demonstrates that a proportion of Spike can simultaneously interact with multiple ACE2 dimers, indicating that more than one RBD domain in a Spike trimer can adopt an ACE2-accessible “up” conformation.

TL;DR: In this article, the effects of somatic mutation on the properties of SARS-CoV-2 spike receptor-binding domain (RBD)-specific antibodies were analyzed and it was shown that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying SARS CoV2 populations, and perhaps against other pandemic threat coronaviruses.

TL;DR: Two class 4 anti-RBD antibodies derived from COVID-19 donors that exhibited broad recognition and potent neutralization of zoonotic coronavirus and SARS-CoV-2 variants are characterized and facilitate vaccine design and illustrate potential advantages of class 4 RBD-binding antibody therapeutics.

TL;DR: Analysis of antibody Fc regions revealed that binding to activating Fc receptors is essential for optimal protection against SARS-CoV-2 MA and that in vivo testing is required to establish optimal hu-mAb combinations for COVID-19 prevention.